Advanced Viral Research Corp.: First Patient Enrolled in Phase II Cancer Trial

YONKERS, N.Y.--(BUSINESS WIRE)--A new Phase II open label study at McGill University will explore the effect of an investigational drug on patients with recurrent or advanced cancer. Researchers indicate the treatment may help patients who suffer from severe appetite loss, fatigue and weight loss when undergoing aggressive cancer therapy. Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, today announced the enrollment of the first patient into the Phase II clinical trial.